LHLabcorp Holdings Inc.
AI adoption · Q1 2026 earnings call
Health CareScaling
7
extracted from this call
3 / 5
operational, no hard numbers
Not disclosed
no breakout in this call
Labcorp discussed AI across multiple dimensions on this call: as a feature embedded in its consumer-facing MyLabcorp app (AI assistant for scheduling/payments), as a clinical decision-support tool via the PathAI digital pathology platform, as an infrastructure for Alzheimer's research via an agentic AI platform with AWS and Datavant, and as an operational efficiency driver through a new collaboration with Optum.ai. Management framed AI as central to both its LaunchPad cost-efficiency initiative and its revenue growth strategy in specialty diagnostics and consumer health. No financial quantification of AI-specific revenue or cost savings was provided.
Adopter
See full leaderboard →47/ 100
76
stage: scaling · max spec: 3
0
no quantified disclosure
85
3 scopes
internal_useproduct_embeddedproduct_standalone
7 AI mentions from this call.
Extracted verbatim from the LH Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.
- T3Q&A· CEO· Internal useyou're launching the MyLabcorp app in May with the AI assistant. So just given the fact that this has been growing double digits in Consumer Health, and it is a strategic priority, could we see some investments from you over the next couple of years and some DTC efforts? And how should we think about the magnitude of that growth and the expenses there? And how should we think about ROI?
“as I start to think about AI, I think about it in multiple ways. One, what can we do to improve customer experience? What can we do in order to try to drive revenue? The second thing is how do we drive operational efficiency from it? Or how do we change processes? And you've seen us talk about certain things that we're doing with digital pathology and microbiology and things that we're doing in cytology, all these things will help to reduce costs over time. We've talked about things that we're doing with billing using artificial intelligence in order to reduce bad debt.”
— Adam Schechter, LH earnings call - T3Prepared remarks· CEO· Product-embedded AI
“A strategic collaboration with Optum.ai to apply AI capabilities to streamline laboratory operations, improve efficiency and enhance the patient and provider experience, providing clear insights to patients about their health, test progress and next steps in care. For physicians, it will help in ordering clinically appropriate tests upfront, reduce administration delays and speed patient access to results.”
— Adam Schechter, LH earnings callOptum.ai - T3Prepared remarks· CEO· Product-embedded AI
“An expansion of our collaboration with PathAI to deploy an FDA-cleared digital pathology platform across our national anatomic pathology labs and hospital laboratory collaboration. This platform embeds AI into everyday clinical decision-making by enabling pathologists to review and manage cases digitally, improve turnaround times and increase consistency of results.”
— Adam Schechter, LH earnings callPathAIFDA-cleared digital pathology platform - T3Prepared remarks· CEO· Standalone AI product
“A new AI-powered real-world data platform being developed in partnership with Amazon Web Services and Datavant to accelerate Alzheimer's research. By combining agentic AI with Labcorp's diagnostic and real world data, the goal is to improve patient recruitment for clinical trials and ultimately shorten drug development time lines.”
— Adam Schechter, LH earnings callAmazon Web Services, DatavantAI-powered real-world data platform - T3Prepared remarks· CEO· Product-embedded AI
“MyLabcorp's AI assistant will also help simplify appointment scheduling and payments.”
— Adam Schechter, LH earnings callMyLabcorp - T2Q&A· CEO· Internal useCan you just give us an update on progress there? And you saw 40 bps of margin expansion in the first quarter, continue to point to expansion throughout the year, I think, across both segments.
“a lot of what we're doing right now is thinking how do we use technology, including artificial intelligence, robotics and computation to help us reduce costs but also to improve the customer experience, things like MyLabcorp that we're launching to help patients understand their lab results better, their health better and so forth.”
— Adam Schechter, LH earnings callMyLabcorp - T2Prepared remarks· CEO· Internal use
“we continue to make significant progress on our strategic priority to utilize advanced technologies, including AI and robotics to enhance customer experiences and to improve operational efficiency and productivity.”
— Adam Schechter, LH earnings call
What management wouldn’t quantify.
Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.
- No quantification of AI-related revenue contribution or cost savings provided despite AI being cited as a key LaunchPad driver.
- No detail on the financial terms or investment size of the Optum.ai collaboration.
- No detail on the financial terms or investment size of the AWS/Datavant agentic AI platform.
- No user adoption metrics or productivity metrics disclosed for any AI tool.
- Analyst (David Westenberg, Piper Sandler) asked about ROI on the MyLabcorp app and consumer investments; management did not quantify AI-specific ROI, only affirmed continued investment and double-digit growth in Consumer Health broadly.
- Analyst (Michael Ryskin, Bank of America) asked about LaunchPad margin drivers; management cited AI and technology as key levers but provided no AI-specific cost savings figure.
Compare with peers.
Other companies in the same sector and at the same AI adoption stage.
Same GICS sector, all stages
Independent research, direct to your inbox.
Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.